Although the CXCL12-CXCR4/CXCR7 chemokine axis is demonstrated to play an integral role in tumor progression, the controversy exists and the role of CXCL12-CXCR4/CXCR7 signaling axis in epithelial-mesenchymal transition (EMT) of human ovarian cancer has not been explored. Here, we showed that in ovarian cancer CXCL12 induced EMT phenotypes including the spindle-like cell morphology, podia and stress fiber formation, a decrease in E-cadherin expression, and increases in mesenchymal N-cadherin and vimentin expressions. These effects of CXCL12 could be antagonized by the CXCR4 antagonist AMD3100, but not by the anti-CXCR7
loss of cell polarity and cell-cell adhesion, and acquisition of migratory and invasive properties, leading to gain of mesenchymal stem cell characteristics. 2, 3 EMT programs generally occur in physiological conditions, such as during implantation, embryogenesis, and organ development (type-1 EMT) and in pathological settings, including tissue regeneration and fibrosis (type-2 EMT) as well as cancer progression and metastasis (type-3 EMT). 4 EMT plays a crucial role in peritoneal dissemination of ovarian carcinoma, which is characterized by detachment from the primary tumor, movement into the peritoneal cavity as single cells and multi-cellular aggregates (MCAs) surviving and traveling with intra-abdominal fluid, adhesion to peritoneal tissues and invasion through the mesothelial lining of the peritoneum, followed by anchoring to submesothelial matrix and generating secondary lesions in new distant metastatic organs mediated by mesenchymal-toepithelial transition (MET). 5 There is a great deal of evidence that the network of chemokines and their receptors influences the development of primary tumor and tumor metastasis. 6 Wherein, the chemokine CXCL12 binding to its receptors CXCR4 or CXCR7 has been reported to act as a positive regulator of tumor progression and metastasis. 7, 8 CXCL12-CXCR4 axis is strongly linked to intraperitoneal dissemination of ovarian cancer. 9 Our group and others have corroborated that the CXCL12-CXCR4 chemokine axis plays a critical role in ovarian cancer metastasis through mediating a variety of cellular functions such as cell proliferation, migration, invasion, and adhesion. [9] [10] [11] [12] [13] As one of the major chemokine receptors, CXCR4
has been demonstrated to be aberrantly expressed in a variety of human cancers, including ovarian cancer, but its expression is low or absent in many normal tissues, including ovary. 6 Therefore, CXCR4
expression is closely related to malignization and poor prognosis for ovarian cancer patients in the clinic. 14 The orphan receptor CXCR7
has been identified as binding to CXCL12 with higher affinity than CXCR4. Recently, mounting evidence indicates that CXCR7 has key functions in promoting tumor development and progression. [15] [16] [17] [18] CXCR7 expresses not only in a wide variety of human malignancies, but also in a large percentage of tumor vasculature, which shows a wide role of CXCR7 in tumor promotion. 15 Recently, several studies have emerged to assess the relationship between EMT and CXCL12/ CXCR4/CXCR7 in human cancers. CXCL12-CXCR4 axis induced EMT process by modulating the non-canonical Hedgehog pathway in pancreatic cancer, 19 as well as by activating the Wnt/β-catenin signaling in colorectal cancer. 20 CXCR7 was involved in TGFβ1-promoted EMT in lung cancer. 21 However, to our knowledge, none has investigated comprehensively the function of CXCL12-CXCR4/CXCR7 axis in EMT progression in ovarian cancer, and analyzed their respective role in this process. To address this issue, we used ovarian cancer cell lines IGROV-1 and HO-8910, recombinant human CXCL12, CXCR4
antagonist AMD3100, anti-CXCR7 neutralizing antibody, knockdown of CXCR4 and CXCR7, and overexpression of CXCR4 to investigate the function of CXCL12-CXCR4/CXCR7 signaling in cellular phenotypes and expression of EMT markers. This study may help us better understand the mechanism of ovarian cancer metastasis and provide a potential therapeutic strategy to prevent ovarian cancer progression.
| MATERIALS AND METHODS

| Cell culture
The human ovarian cancer cells lines (IGROV-1 and HO-8910) were from ATCC (Rockefeller, MD), and cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin in an atmosphere of 5% CO 2 /95% air at 37°C. Before drug treatment, ovarian cancer cells in log phase growth were plated in the cell culture plate with an appropriate number of cells depending on the particular assay, and cultured at 37°C for 24 h. The drugs were administered at given concentrations in medium containing 2% (v/v) FBS, and then the cells were incubated for another indicated times. Cell culture media and supplements used in this study were all purchased from Hyclone Laboratories, Inc (Logan, UT).
| RNA interference
The small interfering RNAs (siRNA) duplexes were synthesized by Sangon Biotech (Shanghai) Co., Ltd. The sequence of CXCR4 siRNA was 5′-CCGACCUCCUCUUUGUCAUTT-3′ (sense) and 5′-AUGA-CAAAGAGGAGGUCGGTT-3′ (anti-sense). The sequence of CXCR7
siRNA was 5′-GGCUAUGACACGCACUGCUACAUCU-3′ (sense) and 5′-AGAUGUAGCAGUGCGUGUCAUAGCC-3′ (anti-sense). The sequence of negative control siRNA was 5′-UUCUCCGAACGUGUCAC-GUTT-3′ (sense) and 5′-ACGUGACACGUUCGGAGAATT-3′ (antisense). Ovarian cancer IGROV-1 cells were transfected with the siRNA duplexes for 6 h using Lipofectamine 3000 (Invitrogen, Carsbad, CA)
according to the manufacturer's instructions. After incubation with fresh media for another 48 h, the cells were harvested for RT-PCR or immunoblot analysis.
| CXCR4 overexpression
The DNA fragment encoding the CXCR4 gene (GenBank® accession number NM_003467) was amplified from human cDNA with the CXCR4 primers (sense, 5′-CCGGAATTCGCCACCATGGAGGG- 
| Immunoblotting
The immunoblot analysis was performed as we described previously. 22 The cells were lysed with RIPA buffer (Roche, Basel, Switzerland), and protein concentration was measured using the BCA protein assay. The proteins (30 µg) were subjected to 8-10% 
| Confocal laser scanning microscopy
Filamentous actin (F-actin) staining was performed as we described previously. 12 Briefly, the cells were fixed for 2 h and then counterstained with DAPI at room temperature.
Images were obtained using the Leica confocal laser-scanning microscope (Leica).
| RT-PCR
Total RNA in the cells was extracted using TRIzol reagent (Invitrogen), and reverse transcribed using the PrimeScript™ RT reagent Kit (TaKaRa, Dalian, China) according to the manufacturer's protocol.
The real-time experiments were performed using SYBR ® Premix Ex Taq™ (TaKaRa) and conducted on a CFX96 real-time PCR system (BioRad). The primer sequences were listed in Supplementary Table S1 and purchased from the Sangon Biotech Co., Ltd. The relative gene expression was analyzed using the 2 −ΔΔCt method with GAPDH as the normalization control. 
| Xenograft tumor models
| Histological and immunohistochemical analysis
The tumors dissected from intraperitoneally injected nude mice were fixed using 4.0% (v/v) paraformaldehyde overnight and then embedded in paraffin wax. The tumor sections (4 µm thick) were stained with hematoxylin and eosin for histological analysis. For immunohistochemical analysis, the sections were dewaxed in xylene and rehydrated in grade alcohols, followed by antigen retrieval in citrate buffer. After blockade of endogenous peroxidase activity in 3% hydrogen peroxide, the sections were incubated with the primary antibodies overnight, followed by incubation with goat anti-rabbit IgG (ZSGB Biotechnology Co., Ltd., Beijing, China). After rinsing, the sections were incubated with AEC (Solarbio, Beijing, China), counterstained with hematoxylin, and then analyzed by a light microscope (Zeiss).
| Statistical analyses
Statistical analyses were conducted by GraphPad Prism 5.0 software.
Data were presented as mean ± standard deviation (SD). Paired t-test was used to calculate comparisons between two groups. One-
way ANOVA was used to analyze differences among groups.
P values < 0.05 were considered statistically significant.
3 | RESULTS
| CXCL12 mediated motility of ovarian cancer cells
We firstly performed the transwell migration assay to qualitatively observe the effect of CXCL12 on chemotactic motility of ovarian cancer IGROV-1 and HO-8910 cell lines. After allowing the cells to traverse through the filter membrane for 24 and 48 h respectively, we observed a concentration-dependent increase in the number of migration cells with the increasing concentration of CXCL12 in the lower chamber ( Figures 1A and 1B) . Further, the competitive chemotaxis assay was performed to assess the ability of CXCL12 to induce chemotaxis. As expected, Figure 1C showed that the cells migrated efficiently in response to 20% (v/v) FBS without CXCL12 in the upper chamber. In contrast, no significant migration was observed when CXCL12 was present in the upper chamber with 20% FBS in the lower chamber ( Figure 1C ). These data indicated CXCL12 has obvious competitive advantage for inducing chemotaxis. The CXCL12-treated cells displayed the appearance of N-cadherin staining at the cell-cell contacts ( Figure 3C ), and showed enhanced staining for vimentin as compared with the untreated cells ( Figure 3D ).
After incubation with CXCL12 (100 ng/mL) for 24 h, immunoblot images revealed that the expression of E-cadherin was significantly decreased, whereas that of N-cadherin and vimentin was remarkably increased in the CXCL12-treated cells compared with the untreated cells ( Figure 4A ). In addition, the protein levels of ZEB1, ZEB2, Twist1, β-catenin, MMP-2, and MMP-9, critical proteins for the progression and maintenance of EMT, were significantly increased by CXCL12 treatment as compared with the control (Figure 4A ). The mRNA levels 
| The modulation of CXCR4 and CXCR7 expression influenced EMT process
Before investigating the role of CXCR4 and CXCR7 on CXCL12-induced EMT, we analyzed whether the expression of CXCR4 and CXCR7 regulated the levels of EMT markers in ovarian cancer cells. 5F ). CXCR7 knockdown did not affect expression of E-cadherin, N-cadherin, and vimentin, as well as CXCR4 levels ( Figures 5E and 5F ). These results suggested that CXCR4 rather than CXCR7 is implicated in regulating EMT process in ovarian cancer cells.
| CXCL12 promoted EMT process in a CXCR4-dependent manner in ovarian cancer cells
To further investigate the mechanism underlying CXCL12-induced EMT, we used a CXCR4 antagonist AMD3100 and a neutralizing anti-CXCR7 antibody to prevent the function of CXCR4 and CXCR7, respectively. Cells were treated with 100 ng/mL of CXCL12 in combination with 1 µg/mL of AMD3100 (CXCL12 + AMD3100), 10 µg/mL of anti-CXCR7 antibody (CXCL12 + anti-CXCR7), or 10 µg/mL of its isotype control antibody (CXCL12 + IgG) for 24 h. In IGROV-1 cells, the spindle-like morphology induced by CXCL12 was significantly abolished by AMD3100 treatment (Figure 6A ), ( Figure 6B ). However, anti-CXCR7 antibody treatment did not affect these CXCL12 effects, except for slightly reducing CXCL12-stimulated stress fibers (Figures 3, 6A , and 6B). Thus, these data indicated that CXCL12 induced the appearance of mesenchymal phenotype and the formation of podia in a CXCR4-dependent manner.
We subsequently assessed the effect of AMD3100 and anti-CXCR7 antibody on EMT markers expression. Consistent with immunofluorescence analysis, higher levels of E-cadherin, and lower levels of N-cadherin and vimentin were observed in AMD3100-treated cells, as compared with that in CXCL12-treated cells by immunoblot analysis ( Figure 6C ). In addition, AMD3100 treatment reversed the up-regulation of ZEB1, ZEB2, Twist1, β-catenin, MMP-2, and MMP-9 upon CXCL12 stimulation ( Figure 6C ). The similar inhibitory effect of AMD3100 on CXCL12-induced EMT was observed at mRNA levels by RT-PCR analysis ( Figure 6D ). However, the anti-CXCR7 antibody failed to reverse the reduction of E-cadherin and the enhancement of N-cadherin and vimentin expression levels caused by CXCL12 ( Figure 6E ). The finding was confirmed by the knockdown of FIGURE 4 Effects of CXCL12 on EMT markers expression in ovarian cancer cells. After 24-h incubation, CXCL12 stimulation caused a decline in expression of E-cadherin, whereas a rise in that of N-cadherin, vimentin and key EMT transcription factors at the protein levels in both IGROV-1 and HO-8910 cells (A), and at the mRNA levels in IGROV-1 cells (B). GAPDH was used as a loading control. Data are presented as mean ± SD (n = 3). *P < 0.05, **P < 0.01 CXCR7 ( Figure 6F ). Additionally, there was no significant difference in mRNA levels of these proteins and EMT transcription factors between CXCL12 + IgG and CXCL12 + anti-CXCR7 treatment ( Figure 6D ).
These results suggested that CXCL12 can promote ovarian cancer EMT process via its interaction with CXCR4 rather than CXCR7.
| CXCR4 antagonist AMD3100 inhibited the development of peritoneal metastasis in vivo
To further investigate the role of CXCR4 in ovarian tumor development and metastasis, ovarian cancer IGROV-1 cells were implanted intraperitoneally into the immunodeficient female mice with or without subsequent administration with AMD3100 (5 mg/kg) to examine the peritoneal metastatic potential. The nude mice administrated with AMD3100 showed fewer and smaller disseminated tumors throughout the peritoneal cavity than the untreated mice ( Figure 7A ). The untreated mice displayed more incidence of metastasis in the abdominal organs and heavier tumor weight of disseminated tumors when compared with the AMD3100-treated mice ( Figures 7B and 7C) . Additionally, AMD3100 administration significantly reduced the mRNA levels of EMT transcription factors in tumors dissected from the nude mice ( Figure 7D ). The immunohistochemical detection showed that the tumors from the AMD3100-treated mice had higher E-cadherin and lower N-cadherin and vimentin immunoreactivity than the tumors from the untreated mice ( Figure 7F ), which was consistent with the immunoblot analysis for the proteins from the tumors ( Figure 7E ).
FIGURE 5
Effects of CXCR4 and CXCR7 on expression of epithelial and mesenchymal markers in ovarian cancer cells. The introduction of si-CXCR4 effectively down-regulated the expression of CXCR4, N-cadherin and vimentin, whereas significantly up-regulated E-cadherin expression without affecting CXCR7 levels in IGROV-1 cells by immunoblot analysis (A) and RT-PCR analysis (B). The recombinant pcDNA3.1/ CXCR4 plasmid significantly increased the expression of CXCR4, N-cadherin, and vimentin, whereas dramatically decreased E-cadherin expression in HO-8910 cells by immunoblot analysis (C) and RT-PCR analysis (D). The CXCR7 knockdown did not affect the expression of CXCR4 and EMT markers at both the protein levels (E) and the mRNA levels (F) in IGROV-1 cells. GAPDH was used as a loading control. Data are presented as mean ± SD (n = 3). *P < 0.05, **P < 0.01
EMT is a dynamic and reversible process implicated in cancer progression, metastasis, and drug resistance, which is a key characteristic of human malignant tumors including ovarian cancer. 23 Tan et al showed that the EMT status was linked to overall survival in ovarian cancer, and patients with epithelial ovarian cancer had a better prognosis in terms of disease-free survival. 24 Elevated CXCL12 levels and its cognate receptor CXCR4 expression were associated with higher grades, increased risk of recurrences, and poorer survival in ovarian cancer. 14, 25 The evidence indicated a possible correlation between CXCL12 axis and EMT in ovarian cancer.
The epithelial cancer cells undergoing EMT suffer a series of molecular, morphological, and functional changes with the resultant of impairment of epithelial cell-cell contacts. In the current study, we observed CXCL12 stimulation significantly promoted chemotactic migration in a concentration-dependent manner (Figure 1 ), accompanied by acquirement of a spindle-like morphology (Figure 2 ), formation of stress fibers and podia ( Figure 3A) , and switch of E-cadherin to N-cadherin at the cell-cell contacts ( Figures 3B and 3C) . The enhanced The anti-CXCR7 antibody (E) and the knockdown of CXCR7 by si-CXCR7 (F) failed to reverse the reduction of E-cadherin and the enhancement of N-cadherin and vimentin expression levels caused by CXCL12. GAPDH was used as a loading control. Data are presented as mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 cell migration is a hallmark of tumor EMT progression in epithelial carcinoma. A spindle-shaped morphology of cell lines showed a higher EMT score than cell lines without a spindle-like morphology. 24, 26 The remodeling of actin cytoskeleton directly influences the metastatic capability of cancer cells. 27 EMT is implicated in molecular reprogramming of cell, usually is characterized by redistribution or loss of epithelial-specific junction proteins (e.g., E-cadherin) and unlocking of mesenchymal markers (e.g., vimentin and N-cadherin).
28
CXCL12 treatment elicited the down-regulation of E-cadherin, and the up-regulation of N-cadherin, vimentin, β-catenin, MMP-2, MMP-9, and known EMT inducers, including the Snial family (Snail1 and Snail2), the ZEB family (ZEB1 and ZEB2), and the Twist family (Twist1 and Twist2) ( Figure 4A ). It has been confirmed that these EMT inducers bound to E-cadherin promoter to repress E-cadherin transcription directly (Snail and ZEB) or indirectly (Twist). 3 Stemmer et al showed that Snail could stimulate the activity of Wnt pathway by down-regulation of E-cadherin leading to the release of β-catenin and increase of cytoplasmic β-catenin. 29 The shedding of E-cadherin ectodomain induced epithelial ovarian cancer cells detaching from tumor surface and disseminating into the peritoneal cavity, destroyed existing cell junction between epithelial ovarian cancer cells, and promoted cancer cell invasion by triggering the up-regulation of MMP-2 and MMP-9 expression. 5, 30 Growing evidence supports that CXCR4 acts as a positive regulator for tumor cell metastasis. 10, 14 CXCR4 enhanced the acquisition of an EMT-like signature in multiple myeloma cells resulting in higher bone metastasis and extra-medullary disease dissemination in vivo. 4 High CXCR4 expression was strongly associated with low E-cadherin expression, high N-cadherin, and vimentin expression in colon cancer tissues. 20 In the present study, we observed that CXCR4
knockdown by si-CXCR4 up-regulated E-cadherin and down- Meanwhile, CXCR7 rather than CXCR4 regulated TGFβ1-induced EMT, and cell migration and invasion in lung cancer. 21 Yu et al verified that CXCL12-CXCR7 axis enhanced cell invasion by MMP-9 expression through p38 MAPK pathway in ovarian cancer. 33 CXCR7
promoted EMT of bladder cancer by activating AKT, ERK, and STAT3 pathways. 17 Interestingly, we did not observe any alteration of EMT-related markers expression by the knockdown of CXCR7
( Figures 5E and 5F ). Additionally, the treatment of anti-CXCR7
blocking antibody failed to reverse the effect of CXCL12 on cellular morphology ( Figure 6A ), podia formation ( Figure 3A ), cell movement ( Figure 6B ), and EMT makers expression ( Figures 3B-D, 6D , and 6E). In this study, CXCR7 was not involved in CXCL12-induced EMT in ovarian cancer. Our finding seemed discrepant with the mentioned reports. We proposed that CXCR7 mediating EMT process of tumor cells may be in a strictly context-and cell type-specific manner. Hence, further studies need to be undertaken to investigate the function of CXCR7 in ovarian tumor progression and the underlying mechanism.
In this study, the data revealed that CXCL12 may be a strong inducer of pathological EMT during tumor development. Its corresponding receptor CXCR4, rather than CXCR7 was implicated in this process in ovarian carcinoma. Our study was the first time to show the role of CXCL12-CXCR4/CXCR7 chemokine axis in EMT progression of ovarian cancer. Targeting the axis may prove beneficial for the prevention of tumor metastasis, and provide a more promising therapeutic strategy for ovarian cancer.
